My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 804 / https://doi.org/10.3332/ecancer.2018.804

Research

Men seeking counselling in a Breast Cancer Risk Evaluation Clinic

Background: Hereditary breast and ovary cancer syndrome affects both genders but little is known about the uptake of genetic services by men. The objective of this study is to characterise the male population counselled through a multidisciplinary breast/ovarian program.

Methods: Descriptive analysis of male patients counselled from January 2000 to December 2015. Data in this analysis include new cancer diagnoses during prospective follow up.

Results: From 4,320 families registered, 362 male patients were identified: 236 (65.2%) from hereditary cancer families (HCF) and 126 (34.8%) from non-HCF. In HCF, 121 patients (51.3%) were mutation carriers (MC): BRCA2 – 102 (84.3%), BRCA1 – 16 (13.2%), CHEK2 – 1 (0.8%) and TP53 – 2 (1.7%). Non-HCF included 126 patients: 85 (67.5%) belonged to families without pathogenic mutations or with variants of unknown clinical significance; 22 (17.5%) refused testing after counselling and 19 (15.0%) did not meet criteria for testing. Both HCF and non-HCF included patients with previous cancer diagnoses: HCF- Breast Cancer (BC) - 18; prostate cancer (PC) - 13; melanoma - 1; others - 7) and non-HCF (BC - 77; PC - 20; gastric cancer (GC) - 1; melanoma - 8; bladder cancer - 1; others - 22). From the 121 MC identified (including the TP53 and CHEK2 carriers), 97 patients (80.2%) adhered to prospective surveillance. With a median follow-up of 36.9 months, 17 cancers were diagnosed in 14 patients, PC being the most frequently diagnosed neoplasia (5 cases). Eleven patients (78.6%) are alive and three patients died of advanced cancer (2 with GC, 1 with disseminated adenocarcinoma).

Conclusion: We observed a high adherence to counselling, genetic testing and active surveillance by men belonging to hereditary BC families. Male carriers of pathogenic DNA variants are at risk for several cancers and should be included in prospective follow-up studies.

Keywords: hereditary cancer, germline mutations, genetic counselling, genetic testing, breast cancer, prostate cancer, surveillance program

Loading Article Metrics ... Please wait

Related articles

Short Communication: Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica

Abstract | Full Article | PDF Published: 24 Apr 2018 / https://doi.org/10.3332/ecancer.2018.829

Review: The current state of prostate cancer treatment in Trinidad and Tobago

Abstract | Full Article | PDF Published: 24 Apr 2018 / https://doi.org/10.3332/ecancer.2018.828

Research: Nursing intervention in women who developed lymphedema after undergoing a modified radical mastectomy: a pre-experimental study

Abstract | Full Article | PDF | Spanish Published: 19 Apr 2018 / https://doi.org/10.3332/ecancer.2018.827

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Abstract | Full Article | PDF Published: 16 Apr 2018 / https://doi.org/10.3332/ecancer.2018.825

Review: Adipose tissue stem cells in regenerative medicine

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2018 / https://doi.org/10.3332/ecancer.2018.822



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence